• 1.
    Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood. 2008;111:48714879.
  • 2.
    Vigué B. Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe haemorrhage—from theory to practice. Crit Care. 2009;13:209.
  • 3.
    Friedman RJ, Gallus AS, Cushner FD, et al. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin. 2008;24:8797.
  • 4.
    Pengo V, Pegoraro C, Cucchini U, et al. Worldwide management of oral anticoagulant therapy: the ISAM study. J Thromb Thrombolysis. 2006;21:7377.
  • 5.
    Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287:337344.
  • 6.
    Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med. 2007;167:14141419.
  • 7.
    Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis. 2011;31:326343.
  • 8.
    Zikria J, Ansell J. Oral anticoagulation with Factor Xa and thrombin inhibitors: is there an alternative to warfarin? Discov Med. 2009;8:196203.
  • 9.
    Kimmel SE. Warfarin therapy: in need of improvement after all these years. Expert Opin Pharmacother. 2008;9:677686.
  • 10.
    Prasad S, Wootten MR, Kulinski N, et al. What to do when warfarin therapy goes too far. J Fam Pract. 2009;58:346352.
  • 11.
    Aguilar MI, Hart RG, Kase CS, et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc. 2007;82:8292.
  • 12.
    Wiedermann CJ, Stockner I. Warfarin-induced bleeding complications—clinical presentation and therapeutic options. Thromb Res. 2008;122(suppl 2):S13S18.
  • 13.
    Pabinger I, Tiede A, Kalina U, et al. Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: a prospective clinical trial of emergency anticoagulation reversal. Ann Hematol. 2010;89:309316.
  • 14.
    Xarelto (rivaroxaban) [package insert]. Titusville, NJ: Janssen Pharmaceuticals. 2011.
  • 15.
    Roehrig S, Straub A, Pohlmann J, et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct Factor Xa inhibitor. J Med Chem. 2005;48:59005908.
  • 16.
    Johnson & Johnson Pharmaceutical Research & Development. Rivaroxaban for the prevention of stroke and non-central nervous system (CNS) systemic embolism in patients with atrial fibrillation. Advisory committee briefing document; 2011.
  • 17.
    Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:27652775.
  • 18.
    Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372: 3139.
  • 19.
    Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:27762786.
  • 20.
    Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373: 16731680.
  • 21.
    Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365: 883891.
  • 22.
    dummy Pradaxa (dabigatran etexilate capsules) [package insert]. Ingelheim, Germany: Boehringer Ingelheim Pharma GmbH & Co. 2011.
  • 23.
    Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:11161127.
  • 24.
    Lubetsky A, Yonath H, Olchovsky D, et al. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med. 2003;163:24692473.
  • 25.
    Bershad EM, Suarez JI. Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature. Neurocrit Care. 2010;12:403413.
  • 26.
    Lisman T, Bijsterveld NR, Adelmeijer J, et al. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost. 2003;1: 23682373.
  • 27.
    Hall AB, Carson BC. Reversal of warfarin-induced coagulopathy: review of treatment options. J Emerg Nurs. 2012;38:98101.
  • 28.
    Stanworth SJ, Brunskill SJ, Hyde CJ, et al. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol. 2004;126:139152.
  • 29.
    Leissinger CA, Blatt PM, Hoots WK, et al. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol. 2008;83:137143.
  • 30.
    Goldstein JN, Thomas SH, Frontiero V, et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke. 2006;37:151155.
  • 31.
    Makris M, van Veen JJ, Maclean R. Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. J Thromb Thrombolysis. 2010;29:171181.
  • 32.
    Logan AC, Yank V, Stafford RS. Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Ann Intern Med. 2011;154:516522.
  • 33.
    Yank V, Tuohy CV, Logan AC, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med. 2011;154:529540.
  • 34.
    Skolnick BE, Mathews DR, Khutoryansky NM, et al. Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. Blood. 2010;116:693701.
  • 35.
    Scott LJ. Prothrombin complex concentrate (Beriplex P/N). Drugs. 2009;69:19771984.
  • 36.
    Monroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol. 2006;26:4148.
  • 37.
    Morgenstern LB, Hemphill JC III, Anderson C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010;41:21082129.
  • 38.
    Prothrombin complex concentrates to reverse warfarin-related bleeding. Med Lett Drugs Ther. 2011;53:7879.
  • 39.
    Anti-Inhibitor Coagulant Complex, nanofiltered and vapor-heated lyophilized powder for solution [package insert]. Deerfield, IL: Baxter Healthcare Corporation. 2011.
  • 40.
    Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:15731579.
  • 41.
    Mills RM, Berkowitz RD, Damaraju CV, et al. Initiation of rivaroxaban following low molecular weight heparin for thromboprophylaxis after total joint replacement: the Safe, Simple Transitions (SST) study. Poster presented at: International Society for Thrombosis and Haemostasis (ISTH); July 2329, 2011; Kyoto, Japan.
  • 42.
    Gruber A, Marzec UM, Buetehorn U, et al. Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates. Blood. 2008;112:3825.
  • 43.
    Perzborn E, Harwardt M. Recombinant factor VIIA partially reverses the effects of the factor XA inhibitor rivaroxaban on thrombin generation, but not the effects of thrombin inhibitors, in vitro. J Thromb Haemost. 2007;5(suppl 2): Abstract P-W-640.
  • 44.
    Eerenberg ES, Sijpkens MK, Kamphuisen PW, et al. Prothrombin complex concentrate reverses the anticoagulant effect of rivaroxaban in healthy volunteers. Blood. 2010;116:Abstract 1094.
  • 45.
    Guyatt GH, Norris SL, Schulman S, et al. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e89Se119S.
  • 46.
    Cairns JA, Connolly S, McMurtry S, et al; CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol. 2011;27:7490.